Johnson & Johnson 4Q Revenues: $22.5 billion (+5%) 4Q Earnings: $3.4 billion (-17%) FY Revenues: $88.8 billion (+4%) FY Earnings: $14.1 billion (+6%) Comments: Innovative Medicine sales were $14.3 billion in the quarter, up 4%, and $57.0 billion for the year, up 4%. Growth in the quarter was driven primarily by DARZALEX up 21% to $3.1 billion, ERLEADA up 21% to $784 million, TREMFYA in Immunology, up 4%to $949 million, and SPRAVATO in Neuroscience, up 45% to $297 million. Grow...